News / Korea / yonhap_finance
Alteogen Shares Fall Despite 4.4 Trillion KRW Novartis Deal
Health Technology · Biotechnology · yonhap_finance · 2026-09-03
196170
Alteogen shares dropped over 5% on profit-taking despite announcing a major licensing agreement with Novartis worth up to 4.4 trillion KRW.
What Happened
Major Licensing Deal: Alteogen has signed a licensing and option agreement with Novartis to develop and commercialize subcutaneous formulations using its ALT-B4 technology. The deal could potentially bring the company up to 4.41 trillion KRW upon reaching development and commercial milestones.
Stock Price Volatility: Despite the positive news, Alteogen's stock price experienced a sharp reversal after an initial morning rally. The stock eventually closed at 283,000 KRW, down 5.19% from the previous trading session.
Technological Foundation: The core of the agreement, ALT-B4, is a recombinant human hyaluronidase developed using Alteogen's proprietary Hybrozyme platform. This technology enables the conversion of intravenous drugs into subcutaneous injections, significantly improving patient convenience.
Market Analysis: Analysts attribute the decline to profit-taking following the announcement of the massive deal. The stock's failure to maintain its intraday high of 313,500 KRW suggests that investors were looking to lock in gains after the recent rally.